| Joshua M Burkhart, PA-C | |
|
316 W 2nd St, Morehead, KY 40351-1550 | |
| (859) 562-1540 | |
| Not Available |
| Full Name | Joshua M Burkhart |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Location | 316 W 2nd St, Morehead, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457830580 | NPI | - | NPPES |
| 7100557610 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | PA2387 (Kentucky) | Secondary |
| 363A00000X | Physician Assistant | TC724 (Kentucky) | Secondary |
| 363A00000X | Physician Assistant | PA2387 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joshua M Burkhart, PA-C 316 W 2nd St, Morehead, KY 40351-1550 Ph: (859) 562-1540 | Joshua M Burkhart, PA-C 316 W 2nd St, Morehead, KY 40351-1550 Ph: (859) 562-1540 |
News Archive
BioElectronics Corp., the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the organization is in the process of working with market makers to move the trading of its common shares to the OTCBB quotation system. This comes about as a result of the recent completion of full financial audits for the years 2005 through 2009 and the filing of Form 10K with the U.S. Securities and Exchange Commission. BioElectronics is now a fully reporting company.
Mimetogen Pharmaceuticals Inc. today announced positive top line data from the Phase II clinical trial of MIM-D3 for dry eye disease. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles.
GlaxoSmithKline announced today that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, including BEXSERO (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18).
Usually, mould fungi are nothing to cheer about - but now they can be used as "chemical factories". Scientists at the Vienna University of Technology have succeeded in introducing bacterial genes into the fungus Trichoderma, so that the fungus can now produce important chemicals for the pharmaceutical industry. The raw material used by the fungus is abundant - it is chitin, which makes up the shells of crustaceans.
Diabetes is a known risk factor for morbidity and mortality related to COVID-19. In diabetes patients, rare but severe complications, like the potentially lethal condition diabetic ketoacidosis (DKA), can arise when illness or certain conditions prevent cells from receiving enough glucose to fuel their functioning.
› Verified 6 days ago